JAM
SRPT icon

Jupiter Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Jupiter Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-78,578
Closed -$9.81M – 473
2024
Q3 		$9.81M Buy
+78,578
New +$10.9M 0.09% 227
2024
Q1 		– Sell
-17,140
Closed -$1.65M – 526
2023
Q4 		$1.65M Buy
+17,140
New +$1.64M 0.02% 353
2023
Q1 		– Sell
-24,674
Closed -$3.19M – 496
2022
Q4 		$3.19M Buy
+24,674
New +$2.86M 0.05% 250

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jupiter Asset Management's SRPT Position: Q4 2024 in Review

Jupiter Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 78,578 shares — an estimated $9.81M sold.

Jupiter Asset Management first reported a position in SRPT in Q4 2022 and held it in 3 quarters. The position peaked at $9.81M in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

  • Jupiter Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jupiter Asset Management sold 78,578 Sarepta Therapeutics shares in Q4 2024, an estimated $9.81M.
  • Jupiter Asset Management first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 3 quarters.
  • Jupiter Asset Management's Sarepta Therapeutics position peaked at $9.81M in Q3 2024.
  • 464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Jupiter Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.